Researchers from the nearly 90 NIH-funded groups that make up the Roadmap Epigenomics Consortium have published more than 100 reference epigenomes, along with insights into the role those epigenomes play in several diseases, and methodological papers describing how to gather, analyze and interpret epigenomics data, and commentaries putting the work into perspective. Read More
SHANGHAI – The five month old GPCR Consortium – which brings together industry and academics to explore the G protein-coupled receptors (GPCRs) family of proteins – has added two new pharmaceutical members to its fold. It now counts Novo Nordisk AS and Merck & Co. Inc. as members in addition to founding members Amgen Inc., Ono Pharmaceutical Co. Ltd. and Sanofi SA. Read More
Ebola may not be making as many headlines as it did several months ago, but the outbreak in West Africa continues to be a problem that needs new solutions. To that end, a consortium led by Scripps Translational Science Institute has been formed to develop a program, using digital health technology, to improve health outcomes for Ebola patients, increase the safety of health care workers and reduce the risk of spreading the virus to others. Read More
Heat Biologics Inc. and Oncosec Medical Inc. are joining forces to evaluate the preclinical efficacy of combining Heat's tumor-specific cytotoxic T-cell immunotherapy with Oncosec's Immunopulse intratumoral DNA delivery platform in a bid to expand the impact of their technologies for the benefit of people with cancer. Read More
DUBLIN – Sanofi SA has teamed up with a little-known Dutch biotech company, Lead Pharma Holding BV, in order to move into the hotly contested arena of retinoic acid-related orphan receptor gamma-t (RORγt) inhibition. Read More
The Medicines Co., of Parsippany, N.J., reported worldwide net revenue increased by 3.2 percent to $191 million for the fourth quarter of 2014 from $185 million in the fourth quarter of 2013. Read More
Seeking comments and alternatives to a 2013 proposed generic drug labeling rule, the FDA will hold an all-day public meeting March 27 on the subject. Read More
Dance Biopharm Inc., of Brisbane, Calif., completed a $9.5 million financing consisting of convertible notes and warrants to a syndicate of individual and institutional investors. Proceeds will be used to fund clinical studies and to manufacture drug and devices for studies of Dance 501, the company's inhaled insulin candidate to treat diabetes, as well as for other corporate purposes. Read More
Ferring Pharmaceuticals SA, of Saint Prex, Switzerland, said it has acquired the assets of Biosurface Engineering Technologies Inc., including two phase III ready orthobiologic product candidates designed to improve bone repair. The initial indications for Amplex and Prefix to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively. Read More
Elite Pharmaceuticals Inc., of Northvale, N.J., offered guidance regarding the company's phase III trial with ELI-200, an abuse-deterrent opioid product. Read More
Actavis plc, of Dublin, said it will adopt Allergan as its new corporate name following the anticipated successful completion its acquisition of Allergan Inc. Read More
